71 related articles for article (PubMed ID: 22081480)
1. Test of the month: The chromogenic antifactor Xa assay.
Gehrie E; Laposata M
Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480
[TBL] [Abstract][Full Text] [Related]
2. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
[No Abstract] [Full Text] [Related]
3. Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Linkins LA; Moffat K
J Thromb Haemost; 2014 Sep; 12(9):1570-1. PubMed ID: 25040104
[TBL] [Abstract][Full Text] [Related]
4. More on: is laboratory monitoring of low-molecular-weight heparin necessary?
Shojania AM
J Thromb Haemost; 2004 Dec; 2(12):2276-7. PubMed ID: 15613053
[No Abstract] [Full Text] [Related]
5. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity.
Depasse F; Gerotziafas GT; Busson J; Van Dreden P; Samama MM
J Thromb Haemost; 2004 Feb; 2(2):346-8. PubMed ID: 14996008
[No Abstract] [Full Text] [Related]
6. Laboratory monitoring of low-molecular-weight heparin therapy-part II.
Boneu B
J Thromb Haemost; 2005 Mar; 3(3):573-4. PubMed ID: 15748249
[No Abstract] [Full Text] [Related]
7. Anti-factor Xa (anti-Xa) assay.
Newall F
Methods Mol Biol; 2013; 992():265-72. PubMed ID: 23546719
[TBL] [Abstract][Full Text] [Related]
8. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.
Samuelson BT; Cuker A; Siegal DM; Crowther M; Garcia DA
Chest; 2017 Jan; 151(1):127-138. PubMed ID: 27637548
[TBL] [Abstract][Full Text] [Related]
9. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.
Douxfils J; Ageno W; Samama CM; Lessire S; Ten Cate H; Verhamme P; Dogné JM; Mullier F
J Thromb Haemost; 2018 Feb; 16(2):209-219. PubMed ID: 29193737
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
Mueck W; Stampfuss J; Kubitza D; Becka M
Clin Pharmacokinet; 2014 Jan; 53(1):1-16. PubMed ID: 23999929
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Initial Enoxaparin Dosing and Antifactor Xa Levels in Infants Admitted to the Neonatal Intensive Care Unit.
Nagy R; Hemmelgarn T; Deptola S; Hemmann B
Biomed Hub; 2024; 9(1):54-61. PubMed ID: 38616894
[TBL] [Abstract][Full Text] [Related]
12. Heparin monitoring during extracorporeal membrane oxygenation: the effect of dextran sulfate on anti-Xa assay.
Hammami E; Stiel L; Palpacuer C; Harzallah I
Res Pract Thromb Haemost; 2023 Oct; 7(7):102196. PubMed ID: 38077812
[No Abstract] [Full Text] [Related]
13. Evaluation of the use of a heparin dose-response test in dogs to determine the optimal heparin dose during intravascular procedures and assessment of the in vitro heparin response in healthy dogs.
Hellemans A; Devriendt N; Duchateau L; Devreese KMJ; De Somer F; Bosmans T; Mampaey G; Smets P
Vet Med Sci; 2024 May; 10(3):e1326. PubMed ID: 37987511
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Heparin Monitoring with the Anti-Xa Assay.
Dean CL
Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
[TBL] [Abstract][Full Text] [Related]
15. Current and future strategies to monitor and manage coagulation in ECMO patients.
Zeibi Shirejini S; Carberry J; McQuilten ZK; Burrell AJC; Gregory SD; Hagemeyer CE
Thromb J; 2023 Jan; 21(1):11. PubMed ID: 36703184
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
Monteagudo-Vela M; Bowles C; Raj B; Robinson D; Simon A
Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):322-325. PubMed ID: 34849924
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation Monitoring for Perioperative Physicians.
Maier CL; Sniecinski RM
Anesthesiology; 2021 Oct; 135(4):738-748. PubMed ID: 34499103
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Heparin Anti-Factor Xa Levels Following Antithrombin Supplementation in Pediatric Patients Supported With Extracorporeal Membrane Oxygenation.
Gordon SE; Heath TS; McMichael ABV; Hornik CP; Ozment CP
J Pediatr Pharmacol Ther; 2020; 25(8):717-722. PubMed ID: 33214783
[TBL] [Abstract][Full Text] [Related]
19. Erroneous Activated Coagulation Time During Atrial Flutter Ablation.
Goldstein S; Juarez J; Streiff A
Case Rep Anesthesiol; 2020; 2020():3842051. PubMed ID: 31970000
[TBL] [Abstract][Full Text] [Related]
20. Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.
Ourri B; Francoia JP; Monard G; Gris JC; Leclaire J; Vial L
ACS Med Chem Lett; 2019 Jun; 10(6):917-922. PubMed ID: 31223448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
